Stock data
INmune Bio Inc. (INMB)
INmune Bio Inc. (INMB) reported revenue of US$0.05M and net income of -US$45.93M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$0.05M | — | -US$47.38M | -US$45.93M | — |
| 2024 | US$0.01M | — | -US$42.63M | -US$42.08M | — |
| 2023 | US$0.15M | — | -US$29.74M | -US$30.01M | — |
| 2022 | US$0.37M | — | -US$25.95M | -US$27.30M | — |
| 2021 | US$0.18M | — | -US$29.15M | -US$30.34M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$1.27M | — |
| 2026-03-31 | — | -US$5.41M | — |
| 2025-12-31 | — | -US$5.26M | — |
| 2025-09-30 | — | -US$6.47M | — |
| 2025-06-30 | — | -US$24.46M | — |
| 2025-03-31 | US$0.05M | -US$9.74M | — |
| 2024-12-31 | — | -US$9.22M | — |
| 2024-09-30 | — | -US$12.09M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.